Enkang Pharma Secures Series B Funding for DRIPs-Targeted Cancer Therapy
Enkang Pharmaceutical Technology (Guangzhou) Co., Ltd, a developer of DNA replication-initiation proteins (DRIPs)-targeted drugs, has...
CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
Zennova Pharmaceuticals Completes Phase 1 of Chengdu Manufacturing and R&D Center
Zennova Pharmaceuticals Group, a contract manufacturing organization (CMO) with operations in New Jersey, US, and...
Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of...
China Unveils Measures to Boost Foreign Investment in R&D Centers
The Ministry of Commerce and Ministry of Science and Technology, with the agreement of the...
Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
RemeGen and Allist Partner to Assess ADC and EGFR Inhibitor Combination in NSCLC
China-based RemeGen Ltd (HKG: 9995) and Allist Pharmaceuticals Inc. (SHA: 688578) have announced a clinical...
HealZen Therapeutics Gains NMPA Approval for HZ-A-018 Clinical Study in Autoimmune Diseases
Hangzhou-based HealZen Therapeutics has announced receiving approval from the National Medical Products Administration (NMPA) to...
Betta Pharmaceuticals’ BPI-D0316 Accepted for Review by CDE for First-Line NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that another market approval filing for...
Jiangsu Alpha Biopharma’s Zorifertinib NDA Accepted for Review by CDE
China-based Jiangsu Alpha Biopharma Ltd has announced that the New Drug Application (NDA) for its...
Grand Pharma’s Jext Auto-Injector Approved for Import into Greater Bay Area
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced receiving official approval from the Guangdong...
Abbisko’s ABSK021 Receives FDA Breakthrough Therapy Designation for TGCT
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving breakthrough therapy designation (BTD)...
CDE Grants Priority Review Status to Kechow’s HL-085 for Melanoma Treatment
The Center for Drug Evaluation (CDE) website indicates that Kechow Pharma’s HL-085 is set to...
NMPA Approves Two China-Developed COVID-19 Small-Molecule Therapies
The National Medical Products Administration (NMPA) has issued conditional marketing approvals to two novel, China-discovered...
China’s NHC Issues Guidelines to Improve Pediatric Medication Management
The National Health Commission (NHC) has released a notification aimed at refining management measures for...
China’s Multi-Bureau Plan Aims to Eradicate Cervical Cancer by 2030
The National Health Commission (NHC), Ministry of Education, Ministry of Civil Affairs, and six other...
JS InnoPharm’s US Subsidiary Initiates Phase I Trial for AURKA Inhibitor VIC-1911
Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by...
Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab
Akeso Inc. (HKG: 9926) has announced receiving the first installment of USD 300 million as...
NMPA Proposes Emergency Use Management Measures for Medical Devices
The National Medical Products Administration (NMPA) has released the “Medical Device Emergency Use Management Measures”...
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...